Cantor Fitzgerald Cuts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $61.00

Celldex Therapeutics (NASDAQ:CLDX) had its target price trimmed by Cantor Fitzgerald from $67.00 to $61.00 in a report published on Wednesday,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock.

CLDX has been the subject of several other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Friday, July 17th. Canaccord Genuity Group dropped their price objective on shares of Celldex Therapeutics from $62.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday. Wells Fargo & Company increased their target price on shares of Celldex Therapeutics from $38.00 to $54.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 13th. Wall Street Zen raised shares of Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, July 12th. Finally, Guggenheim boosted their price target on shares of Celldex Therapeutics from $90.00 to $100.00 and gave the company a “buy” rating in a report on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Celldex Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $52.77.

Celldex Therapeutics Trading Down 0.4%

Shares of NASDAQ CLDX opened at $35.28 on Wednesday. Celldex Therapeutics has a one year low of $19.72 and a one year high of $40.30. The firm has a market capitalization of $2.77 billion, a PE ratio of -8.28 and a beta of 0.90. The business has a 50-day moving average price of $33.64 and a two-hundred day moving average price of $30.68.

Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($1.15) by ($0.03). The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.80 million. Research analysts anticipate that Celldex Therapeutics will post -4.36 EPS for the current year.

Institutional Investors Weigh In On Celldex Therapeutics

Several large investors have recently made changes to their positions in the company. Russell Investments Group Ltd. increased its holdings in Celldex Therapeutics by 27.6% in the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 501 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Celldex Therapeutics by 1.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock valued at $798,000 after acquiring an additional 680 shares during the last quarter. ProShare Advisors LLC lifted its stake in Celldex Therapeutics by 6.9% in the fourth quarter. ProShare Advisors LLC now owns 11,973 shares of the biopharmaceutical company’s stock valued at $325,000 after acquiring an additional 773 shares during the last quarter. Handelsbanken Fonder AB grew its position in Celldex Therapeutics by 5.0% in the second quarter. Handelsbanken Fonder AB now owns 27,200 shares of the biopharmaceutical company’s stock worth $1,012,000 after acquiring an additional 1,300 shares in the last quarter. Finally, Panagora Asset Management Inc. grew its position in Celldex Therapeutics by 7.5% in the fourth quarter. Panagora Asset Management Inc. now owns 21,856 shares of the biopharmaceutical company’s stock worth $594,000 after acquiring an additional 1,522 shares in the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.